AU2007311026B2 - Talarazole metabolites - Google Patents
Talarazole metabolites Download PDFInfo
- Publication number
- AU2007311026B2 AU2007311026B2 AU2007311026A AU2007311026A AU2007311026B2 AU 2007311026 B2 AU2007311026 B2 AU 2007311026B2 AU 2007311026 A AU2007311026 A AU 2007311026A AU 2007311026 A AU2007311026 A AU 2007311026A AU 2007311026 B2 AU2007311026 B2 AU 2007311026B2
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutically acceptable
- compound according
- acceptable salt
- talarozole
- metabolites
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002207 metabolite Substances 0.000 title abstract description 35
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 229940097042 glucuronate Drugs 0.000 claims abstract description 6
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 230000003780 keratinization Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 208000025309 Hair disease Diseases 0.000 claims description 2
- 206010051246 Photodermatosis Diseases 0.000 claims description 2
- 241001303601 Rosacea Species 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010021198 ichthyosis Diseases 0.000 claims description 2
- 208000026721 nail disease Diseases 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- 208000003373 basosquamous carcinoma Diseases 0.000 claims 1
- SNFYYXUGUBUECJ-UHFFFAOYSA-N N-{4-[2-ethyl-1-(1,2,4-triazol-1-yl)butyl]phenyl}-1,3-benzothiazol-2-amine Chemical class C=1C=C(NC=2SC3=CC=CC=C3N=2)C=CC=1C(C(CC)CC)N1C=NC=N1 SNFYYXUGUBUECJ-UHFFFAOYSA-N 0.000 description 52
- 229950009878 talarozole Drugs 0.000 description 32
- 241000700159 Rattus Species 0.000 description 19
- 210000003608 fece Anatomy 0.000 description 19
- 241000282472 Canis lupus familiaris Species 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000002700 urine Anatomy 0.000 description 12
- 230000002285 radioactive effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- -1 alkali metal salts Chemical class 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229930182480 glucuronide Natural products 0.000 description 2
- 150000008134 glucuronides Chemical class 0.000 description 2
- 238000005567 liquid scintillation counting Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012440 retinoic acid metabolism blocking agent Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 230000005353 IP-10 production Effects 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 210000004378 sebocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85198906P | 2006-10-17 | 2006-10-17 | |
| US60/851,989 | 2006-10-17 | ||
| PCT/US2007/081685 WO2008049027A1 (en) | 2006-10-17 | 2007-10-17 | Talarazole metabolites |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007311026A1 AU2007311026A1 (en) | 2008-04-24 |
| AU2007311026B2 true AU2007311026B2 (en) | 2012-05-17 |
Family
ID=39314359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007311026A Ceased AU2007311026B2 (en) | 2006-10-17 | 2007-10-17 | Talarazole metabolites |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8188124B2 (enExample) |
| EP (1) | EP2114895A4 (enExample) |
| JP (1) | JP5343267B2 (enExample) |
| KR (1) | KR101419965B1 (enExample) |
| CN (1) | CN101611016B (enExample) |
| AU (1) | AU2007311026B2 (enExample) |
| BR (1) | BRPI0718310A2 (enExample) |
| CA (1) | CA2667053C (enExample) |
| MX (1) | MX2009004096A (enExample) |
| WO (1) | WO2008049027A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| DK2185693T3 (da) | 2007-07-31 | 2019-09-23 | Lifescan Inc | Differentiering af humane embryoniske stamceller |
| CA2954431C (en) | 2007-11-27 | 2021-08-24 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic cells |
| JP5733986B2 (ja) | 2008-02-21 | 2015-06-10 | ヤンセン バイオテツク，インコーポレーテツド | 細胞の付着、培養、及び剥離のための方法、表面改質されたプレート、並びに組成物 |
| EP2942392B1 (en) | 2008-06-30 | 2018-10-03 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
| US9234178B2 (en) | 2008-10-31 | 2016-01-12 | Janssen Biotech, Inc. | Differentiation of human pluripotent stem cells |
| EP2350265B1 (en) | 2008-10-31 | 2019-04-17 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
| KR101774546B1 (ko) | 2008-11-20 | 2017-09-04 | 얀센 바이오테크 인코포레이티드 | 마이크로-캐리어 상의 만능 줄기 세포 배양 |
| KR101687344B1 (ko) | 2008-11-20 | 2016-12-16 | 얀센 바이오테크 인코포레이티드 | 평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물 |
| CN102482643B (zh) | 2009-07-20 | 2016-06-29 | 詹森生物科技公司 | 人胚胎干细胞的分化 |
| SG10201408552YA (en) | 2009-12-23 | 2015-02-27 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
| PH12012501686A1 (en) | 2010-03-01 | 2020-10-19 | Janssen Biotech Inc | Methods for purifying cells derived from pluripotent stem cells |
| RU2587634C2 (ru) | 2010-05-12 | 2016-06-20 | Янссен Байотек, Инк. | Дифференцирование эмбриональных стволовых клеток человека |
| EP3372672A1 (en) | 2010-08-31 | 2018-09-12 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| CN103154237B (zh) | 2010-08-31 | 2016-03-16 | 詹森生物科技公司 | 多能干细胞的分化 |
| PL2853589T3 (pl) | 2010-08-31 | 2018-05-30 | Janssen Biotech, Inc | Różnicowanie ludzkich zarodkowych komórek macierzystych |
| US9248120B2 (en) | 2011-08-23 | 2016-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Reversing intestinal inflammation by inhibiting retinoic acid metabolism |
| FI2794857T3 (fi) | 2011-12-22 | 2026-03-25 | Janssen Biotech Inc | Ihmisen alkion kantasolujen erilaistaminen yksittäisiksi hormonaalisiksi insuliinipositiivisiksi soluiksi |
| CA2866590A1 (en) | 2012-03-07 | 2013-09-12 | Janssen Biotech, Inc. | Defined media for expansion and maintenance of pluripotent stem cells |
| EP3450544A1 (en) | 2012-06-08 | 2019-03-06 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into pancreatic endodrine cells |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| BR112015015714A2 (pt) | 2012-12-31 | 2017-07-11 | Janssen Biotech Inc | suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas |
| ES2837763T3 (es) | 2012-12-31 | 2021-07-01 | Janssen Biotech Inc | Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas |
| DK2938723T3 (da) | 2012-12-31 | 2023-02-20 | Janssen Biotech Inc | Differentiering af humane embryonale stamceller til pancreatiske endokrine celler under anvendelse af hb9-regulatorer |
| WO2015175307A1 (en) | 2014-05-16 | 2015-11-19 | Janssen Biotech, Inc. | Use of small molecules to enhance mafa expression in pancreatic endocrine cells |
| US10420803B2 (en) | 2016-04-14 | 2019-09-24 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells to intestinal midgut endoderm cells |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6486187B1 (en) * | 1996-06-27 | 2002-11-26 | Janssen Pharmaceutica N.V. | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP869A (en) | 1998-01-05 | 2000-09-04 | Pfizer | 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents. |
| IL162533A0 (en) | 2001-12-19 | 2005-11-20 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
| US20060205945A1 (en) | 2004-05-14 | 2006-09-14 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| PL372356A1 (pl) | 2005-01-20 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
-
2007
- 2007-10-17 BR BRPI0718310-0A patent/BRPI0718310A2/pt not_active IP Right Cessation
- 2007-10-17 US US12/311,862 patent/US8188124B2/en not_active Expired - Fee Related
- 2007-10-17 KR KR1020097009986A patent/KR101419965B1/ko not_active Expired - Fee Related
- 2007-10-17 EP EP07854136A patent/EP2114895A4/en not_active Withdrawn
- 2007-10-17 CN CN2007800387031A patent/CN101611016B/zh not_active Expired - Fee Related
- 2007-10-17 JP JP2009533511A patent/JP5343267B2/ja not_active Expired - Fee Related
- 2007-10-17 CA CA2667053A patent/CA2667053C/en not_active Expired - Fee Related
- 2007-10-17 MX MX2009004096A patent/MX2009004096A/es active IP Right Grant
- 2007-10-17 WO PCT/US2007/081685 patent/WO2008049027A1/en not_active Ceased
- 2007-10-17 AU AU2007311026A patent/AU2007311026B2/en not_active Ceased
-
2012
- 2012-05-21 US US13/476,216 patent/US8399495B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6486187B1 (en) * | 1996-06-27 | 2002-11-26 | Janssen Pharmaceutica N.V. | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010506953A (ja) | 2010-03-04 |
| CA2667053C (en) | 2015-04-28 |
| US8188124B2 (en) | 2012-05-29 |
| EP2114895A1 (en) | 2009-11-11 |
| CN101611016A (zh) | 2009-12-23 |
| US8399495B2 (en) | 2013-03-19 |
| CA2667053A1 (en) | 2008-04-24 |
| AU2007311026A1 (en) | 2008-04-24 |
| CN101611016B (zh) | 2012-01-25 |
| MX2009004096A (es) | 2009-06-16 |
| US20100292284A1 (en) | 2010-11-18 |
| KR101419965B1 (ko) | 2014-07-16 |
| JP5343267B2 (ja) | 2013-11-13 |
| US20120283204A1 (en) | 2012-11-08 |
| KR20090068286A (ko) | 2009-06-25 |
| WO2008049027A1 (en) | 2008-04-24 |
| BRPI0718310A2 (pt) | 2013-11-19 |
| EP2114895A4 (en) | 2011-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007311026B2 (en) | Talarazole metabolites | |
| DE60222137T2 (de) | Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen | |
| DE60106281T2 (de) | Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms | |
| US11827605B2 (en) | Isoquinoline compounds and their use in treating AhR imbalance | |
| WO2021076691A1 (en) | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases | |
| KR20080105124A (ko) | 부프레노르핀 유도체 및 이들의 용도 | |
| US12162902B2 (en) | Decarboxylase inhibitors for treating Parkinson's disease | |
| US20150148370A1 (en) | Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors | |
| EP4089088A1 (en) | Mor receptor agonist compound, preparation method therefor, and use thereof | |
| US9682990B2 (en) | Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors | |
| US20230357240A1 (en) | Novel n-heterocyclic bet bromodomain inhibitor, and preparation method thereof and medical use thereof | |
| JP2005510568A (ja) | アリール基が結合したアザポリサイクリック化合物 | |
| EP1698338B1 (en) | S-methyl-dihydro-ziprasidone for the treatment of schizophrenia | |
| CN115003661B (zh) | 芳基葡糖苷衍生物及其在药物中的用途 | |
| CZ20021435A3 (cs) | Pro-léčiva 6-methoxy-2-naftyloctové kyseliny | |
| US20020132797A1 (en) | DNA-cleaving antitumor agents | |
| US20250129055A1 (en) | Glucoside derivative, and preparation method therefor and application thereof | |
| CA1167469A (en) | N - substituted-benzyl-11-endo-amino-5,6,7,8,9,10- hexahydro-2-hydroxy (or methoxy)-6,9- methanobenzocyclooctene (or nonene) centrally-acting analgesics | |
| CN121342759A (zh) | 二氢喹唑啉酮类化合物及其制备方法和应用 | |
| ES2794560T3 (es) | Derivado de amina cíclica y utilización farmacéutica del mismo | |
| KR820001304B1 (ko) | 펜아탄올아민의 제조방법 | |
| JPH0689020B2 (ja) | グリゼオール酸のモノエステル誘導体 | |
| CA2518100A1 (en) | Use of non-immunosuppressive pipecolic acid derivatives for inducing chondrogenic differentiation | |
| HK40007517B (en) | Immunomodulator compounds | |
| HK40007517A (en) | Immunomodulator compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |